Compounds

Compound Name Developer(s)
1599 Microbiotix, Inc.
Actinomycete metabolites
Adamantanids
ATP Synthesis Inhibitors Global Alliance for TB Drug Development, University of Auckland
Auranofin The Aurum Institute NPC
AZD5847 AstraZeneca
Bedaquiline Janssen Research & Development, LLC
Bi-functional Molecules
Bortezomib SPRINT TB (National University of Singapore)
BTZ 043 University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF)
CC-11050 The Aurum Institute NPC
Celecoxib
Celecoxib WBA
Clofazimine Novartis
CPZEN-45
Cyclopeptides
Delamanid Otsuka Pharmaceutical Development & Commercialization, Inc.
DNA metabolism
DprE Inhibitors
DprE Inhibitors
EMB
Energy Metabolism Inhibitors
Everolimus The Aurum Institute NPC
Faropenem WBA
Folate Biosynthesis Inhibitors
Gatifloxacin
GSK 070, GSK 3036656 GlaxoSmithKline
Gyrase B Inhibitor
GyrB Inhibitors
HE2000
HMG-CoA Reductase Inhibitors
Hsp65 DNA
Immunoxel
IMPDH Inosine monophosphate dehydrogenase inhibitors
Indazoles GlaxoSmithKline, Global Alliance for TB Drug Development
Indoles
InhA Inhibitors
Inhibitors of DosRST signaling and persistence Michigan State University
Inhibitors of isoprenoid biosynthesis
Isoniazid
LeuRS inhibitors GlaxoSmithKline, Anacor Pharmaceuticals
Levofloxacin CDC TBTC, NIAID, NIH, DHHS, Boston University
Macrolides
Malate Synthase Inhibitors
Menaquinone Synthase Inhibitors
Meropenem / Clavulanate
Moxifloxacin Global Alliance for TB Drug Development
Moxifloxacin for Drug-Sensitive TB
MTopo
Mycobacterial Gyrase Inhibitors
Nitazoxanide Weill Medical College of Cornell University
Novel hit-lead programs
OPC-167832 Otsuka Pharmaceutical Development & Commercialization, Inc.
PBTZ 169 iM4TB - Innovative Medicines for Tuberculosis
PBTZ-169 Nearmedic Plus LLC
Phenotypic Hit-to-Lead
PKS13 Inhibitors
Pretomanid Global Alliance for TB Drug Development
Protein Splicing Inhibitors
Pyrazidamide Global Alliance for TB Drug Development
Pyrazinamide Analogs
Pyridomycin
Q203 Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Quinolone DC-159a
Quinolone TBK-613
Rifabutin
Rifampicin St. George's Hospital University of London
Rifampicin PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Rifapentine CDC TBTC, Sanofi
Rifapentine
RNA Polymerase Inhibitors
Ruthenium (II) phosphine/diimine/picolinate complexes
Spectinamide 1810 Microbiotix, Inc.
SPR-113
SPR720 Spero Therapeutics, LLC
SQ109 Sequella, Inc
SQ609 Sequella, Inc
SQ641
Sutezolid Sequella, Inc
TBA-223 Global Alliance for TB Drug Development, Institute of Materia Medica
TBA-354 Global Alliance for TB Drug Development
TBA-7371 Global Alliance for TB Drug Development
TBAJ-587, Diarylquinoline Global Alliance for TB Drug Development, Janssen Research & Development, LLC
TBI-166 Institute of Materia Medica
TGF-B inhib +Cox 2 inhibitor
Thioridazine
TL1 Inhibitors
Trisubstituted benzimidazoles
Tryptanthrins
Ureas
Vitamin D3 The Aurum Institute NPC
Whole cell fragment screens
Whole Cell Hit-to Lead
Whole cell pathway screens
Whole-Cell Hit-to-Lead
Xanthones